The vaccine rollout is going well. There, I said it. An advisory panel at the Centers for Disease Control and Prevention just unanimously approved a vaccine from Johnson & Johnson, which started shipping four million doses of the easier-to-use, one-shot vaccine.

"We think literally within about the next 24 to 48 hours, Americans should start receiving shots in arms," Alex Gorsky, Johnson & Johnson's CEO and chairman of the board, told NBC's Today.

Johnson & Johnson aims to deliver 100 million doses by June and up to a billion by the end of the year. But doomsaying has abounded about the Johnson & Johnson vaccine's efficacy. The Pfizer and Moderna vaccines are both about 95 percent effective at preventing symptomatic COVID-19. Johnson & Johnson rates 65 percent at preventing moderate to severe/critical symptoms. That's also based on research in South Africa where the coronavirus variant is more prevalent. In the US, the Johnson & Johnson vaccine's effectiveness is around 72 percent.

Infectious disease experts say this is still impressive, and it actually wouldn't matter if the rates were lower.

"It's not just how effective a vaccine is. It's how many people get it," Dr. David Priest, an infectious disease specialist with Novant Health, said.

Priest said a good example of that is the annual flu shot.

"The flu vaccine every year, maybe, is 40% effective, but if every eligible person got it, we'd have almost no flu mortality," Priest said.

None of the vaccines will make you bullet proof or anything. However, no deaths or major hospitalizations have been directly linked to the vaccines themselves. They're so safe even the one-term loser and his wife secretly got their shots on their way out the door.

Now, to Dr. David Priest's point, we just need to make sure as many Americans are vaccinated as possible. We didn't actually have a plan for that until the new administration arrived.